Girentuximab - Names and Identifiers
Girentuximab - Reference Information
| Monoclonal antibody | Gituximab (Girentuximab) is a chimeric monoclonal antibody that binds carbonic anhydrase Ⅸ. Carbonic anhydrase Ⅸ is a widely expressed glycoprotein in renal clear cell carcinoma (ccRCC) cells. |
| History | Girentuximab was originally developed by Werex AG in Germany. It was awarded RCC fast-track status and orphan drug designation by the FDA. In January 2017, the Australian biotechnology company Telix Pharmaceuticals Limited announced that it had obtained Girentuximab permission to use as a radioimmunoconjugate. |
| mechanism of action | it triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It activates natural killer cells by binding to carbonic anhydrase IX. |
Last Update：2024-04-09 21:04:16